Recent Posts

Where Our Retinitis Pigmentosa Therapy is Right Now July 17, 2017 - In the past few months, jCyte has made a number of important announcements. In December, we received an $8.3 million grant from the California Institute for Regenerative Medicine (CIRM). In April, we announced our phase Read More >
jCyte Receives Regenerative Medicine Advanced Therapy Designation May 2, 2017 - May 2, 2017 – Cell therapy company jCyte announced that the U.S. Food & Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for the company’s developmental retinitis pigmentosa (RP) treatment, jCell. RMAT seeks Read More >
Powered by CIRM Grant, jCyte Launches New Clinical Trial April 19, 2017 - Phase 2b study will investigate safety and efficacy of retinitis pigmentosa therapy   April 19, 2017 – Cell therapy company jCyte is launching a phase 2b clinical trial to test the safety and efficacy of Read More >